MARKET

KPTI

KPTI

Karyopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.06
-0.06
-0.68%
Opening 09:39 05/06 EDT
OPEN
8.14
PREV CLOSE
8.11
HIGH
8.14
LOW
7.94
VOLUME
116.90K
TURNOVER
--
52 WEEK HIGH
21.82
52 WEEK LOW
7.94
MARKET CAP
604.62M
P/E (TTM)
-2.9599
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 1h ago
CAM Group Holding A Buys Fiserv Inc, Trip. ...
GuruFocus News · 1d ago
10-Q: KARYOPHARM THERAPEUTICS INC.
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations. You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 2d ago
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3)
Benzinga · 2d ago
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., May 4, 2021 /PRNewswire via COMTEX/ -- NEWTON, Mass., May 4, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a...
PR Newswire - PRF · 2d ago
--Wedbush Adjusts Price Target on Karyopharm Therapeutics to $11 From $21, Citing Xpovio Sales Estimates; Neutral Rating Kept
MT Newswires · 2d ago
--RBC Cuts Price Target on Karyopharm Therapeutics to $19 From $24, Maintains Outperform Rating
MT Newswires · 2d ago
53.6% Return Seen to Date on SmarTrend Karyopharm Thera Call (KPTI)
May 04, 2021 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified a Downtrend for Karyopharm Thera (NASDAQ:KPTI) on May 6th, 2020 at $19.31. In...
marketwatch.com · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KPTI. Analyze the recent business situations of Karyopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KPTI stock price target is 25.11 with a high estimate of 49.00 and a low estimate of 11.00.
EPS
Institutional Holdings
Institutions: 250
Institutional Holdings: 74.15M
% Owned: 98.78%
Shares Outstanding: 75.06M
TypeInstitutionsShares
Increased
61
8.14M
New
31
1.72M
Decreased
44
6.50M
Sold Out
21
6.96M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.53%
Pharmaceuticals & Medical Research
-0.65%
Key Executives
President/Chief Executive Officer/Director
Richard Paulson
Co-Founder/Director
Michael Kauffman
Chief Financial Officer/Senior Vice President/Treasurer
Michael Mason
Executive Vice President
Ran Frenkel
Executive Vice President
Tanya Lewis
Executive Vice President
Jatin Shah
Senior Vice President/General Counsel/Secretary
Michael Mano
Senior Vice President
Stephen Mitchener
Chief Scientific Officer
Sharon Shacham
Other
John Demaree
Lead Director/Independent Director
Barry Greene
Independent Director
Garen Bohlin
Independent Director
Mikael Dolsten
Independent Director
Deepika Pakianathan
Independent Director
Mansoor Mirza
Independent Director
Christy Oliger
Independent Director
Deepa Pakianathan
Independent Director
Chen Schor
No Data
  • All
  • Financials
  • Insiders
More
About KPTI
Karyopharm Therapeutics Inc. is an oncology-focused pharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. Its selective inhibitor of nuclear export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Its lead compound, XPOVIOTM (selinexor), received accelerated approval from the Food and Drug Administration (FDA), in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma. Its XPOVIO is an oral SINE compound, which blocks the nuclear export of tumor suppressor, growth regulatory and anti-inflammatory proteins, leading to accumulation of these proteins in the nucleus and enhancing their anti-cancer activity in the cell. It is also focused on developing treatments for other diseases, such as Hematologic Malignancies and Solid Tumor Malignancies.

Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.